Medpace Holdings, Inc. (MEDP) is currently priced at $419.27, showing a slight decrease of $2.1 (-0.498%) from the previous close of $421.37. The trading volume is notable at $222,350, representing a 53.13% increase relative to the average.
In the latest quarterly report released on Tuesday, April 21st, MEDP reported earnings per share (EPS) of $3.92, meeting consensus estimates.
RBC Capital, on April 24th, maintained MEDP's Outperform rating, with the stock price at $393.42. The recommendation remains "hold."
Medpace Holdings generated a free cash flow of $144.97 million, with a significant increase in net cash of $155.63 million. Operating cash flow stood at $151.79 million, with no debt repayment noted.
MEDP reported a revenue of $706.60 million, resulting in a net income of $123.87 million. Earnings per share (EPS) and EPS diluted were $4.35 and $4.28, respectively.
Key ratios for MEDP include a net profit margin of 17.53%, return on equity at 20.7%, and a price-to-earnings ratio of 27.57.
The balance sheet shows MEDP with total assets of $2.13 billion, including cash and cash equivalents of $652.68 million. Total liabilities amount to $1.53 billion, resulting in a net debt of $-506.59 million.
This report provides a comprehensive overview of MEDP's financial performance and market standing.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.